

Client: Example Client ABC123
123 Test Drive
Salt Lake City, UT 84108
UNITED STATES

Physician: Doctor, Example

Patient: Patient, Example

DOB: Unknown
Gender: Unknown
Patient Identifiers: 01234567890ABCD, 012345
Visit Number (FIN): 01234567890ABCD
Collection Date: 00/00/0000 00:00

Autoimmune Vision Loss Panel, Serum

ARUP test code 3016804

CV2 Ab IgG CBA-IFA Screen, Serum

<1:100 (Ref Interval: <1:100)

CV2 Antibody, IgG is not detected. No further testing will be performed.

INTERPRETIVE INFORMATION: CV2 Ab IgG CBA-IFA Screen, Serum

CV2 antibodies aid in discriminating between chronic paraneoplastic neurological disorder (PND) and other inflammatory disorders of the nervous system. Anti-CV2 is associated with small-cell lung cancer and thymoma. A negative test result does not rule out a diagnosis of autoimmune neurologic disease. Results should be interpreted in correlation with the patient's clinical history and other laboratory findings.

This indirect fluorescent antibody assay utilizes CV2 transfected cell lines for the detection and semiquantification of the CV2 IgG antibody.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Recoverin Ab, IgG by Immunoblot, Serum

Negative (Ref Interval: Negative)

INTERPRETIVE INFORMATION: Recoverin Ab, IgG by Immunoblot, Serum

Antibodies to recoverin and CV2/CRMP5 have been associated with paraneoplastic vision loss. Symptoms of vision loss may precede detection of cancer, and a positive test result should prompt a search for malignancy, most often small cell lung adenocarcinoma. A negative test result does not rule out the diagnosis of autoimmune vision loss. Results should be interpreted in the context of the patient's clinical history, neurologic and ophthalmologic exam, and other laboratory findings.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes.

H=High, L=Low, *=Abnormal, C=Critical

VERIFIED/REPORTED DATES

Procedure	Accession	Collected	Received	Verified/Reported
CV2 Ab IgG CBA-IFA Screen, Serum	24-057-100516	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Recoverin Ab, IgG by Immunoblot, Serum	24-057-100516	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00

END OF CHART

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

ARUP LABORATORIES | 800-522-2787 | aruplab.com
500 Chipeta Way, Salt Lake City, UT 84108-1221
Jonathan R. Genzen, MD, PhD, Laboratory Director

Patient: Patient, Example
ARUP Accession: 24-057-100516
Patient Identifiers: 01234567890ABCD, 012345
Visit Number (FIN): 01234567890ABCD
Page 2 of 2 | Printed: 2/26/2024 11:28:38 AM
4848